molmed

Governance

Report on corporate governance and ownership structure 2016 (in Italian) ▾

Report on corporate governance and ownership structure 2016 (in Italian)

Investors

Annual financial report 2017

Annual financial report 2017 ▾

Investors

AIFA set the reimbursement price for Zalmoxis® at EUR 149.000 per infusion, gross of discounts foreseen by law, and also established a flat fee per patient

AIFA set the reimbursement price for Zalmoxis® at EUR 149.000 per infusion, gross of discounts foreseen by law, and also established a flat fee per patient ▾

News & Events

Stay update

Cell and Gene Therapy Manufacturing Congress ▾

Cell and Gene Therapy Manufacturing Congress

Location: Amsterdam RAI Exhibition and Convention Centre

MolMed at this event: Luca Alberici Chief Business Officer at MolMed, Italy Session

Investors

MolMed: completed the fourth tranche of the share capital increase to be reserved to Société Générale

MolMed: completed the fourth tranche of the share capital increase to be reserved to Société Générale ▾

Investors

Submitted the utilization request concerning the fourth tranche of the share capital increase reserved to Société Générale

Submitted the utilization request concerning the fourth tranche of the share capital increase reserved to Société Générale ▾

Investors

Board of Directors approved the first nine months financial report at September 30th, 2017

Board of Directors approved the first nine months financial report at September 30th, 2017 ▾

Investors

Company Presentation November 2017

Company Presentation November 2017 ▾

Last presentation

DOWNLOAD

News & Events

Stay update

COSTEM 2017 Congress on Controversies in Stem Cell Transplantation and Cellular Therapies ▾

COSTEM 2017 Congress on Controversies in Stem Cell Transplantation and Cellular Therapies

Location: Andel's Hotel Berlin, Germany

MolMed at this event: Sponsoring a workshop (Thursday 26th October, 16.45pm-17:45pm)

Investors

New relevant safety data of CD44v6 CAR-T cells will be presented at the 4th International Congress on Stem Cell Transplantation and Cellular Therapies Pdf

New relevant safety data of CD44v6 CAR-T cells will be presented at the 4th International Congress on Stem Cell Transplantation and Cellular Therapies Pdf ▾

Subscribe to

Subscribe to press releases

Dear Users, we would like to inform you that, as of 30 September, AGC Biologics S.p.A. (formerly MolMed S.p.A.) is no longer listed on the Milan Stock Exchange and has become part of the AGC Biologics Group. For any information on the company and the group, you are kindly invited to consult the websitewww.agcbio.com.
The contents present on this portal (www.molmed.com) are updated until the date of September 30, 2020 and will be available for the time frame foreseen by applicable regulations.
In addition, the "work with us" section is still active, while the contact details are no longer accessible.